ArticleDrug design, development and therapy2026
Impact of Estimated Glomerular Filtration Rate Equations on Vancomycin Dosing and Treatment Outcomes.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of adsorptive CRRT membranes on vancomycin pharmacokinetics in critically ill patients.Renal failure · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vancomycin has a narrow therapeutic window and is primarily renally excreted. This study explored whether varied estimated glomerular filtration rate (eGFR) equations lead to differences in chronic kidney disease (CKD) staging and vancomycin dosage, and their impact on treatment outcomes. Methods: This cross-sectional study retrospectively included adult patients receiving vancomycin for therapeutic purposes (empirical or targeted therapy) at Nanjing Drum Tower Hospital (2019-2023). Consistency of each of the metrics (eGFR values, CKD staging, dose staging, and staging recommendations) derived from different equations was compared. Incidences of distinct clinical outcomes were compared among patients receiving doses recommended by different eGFR equations. Logistic regression analyzed associations between inconsistent status and patient characteristics as well as clinical outcomes. Results: A total of 832 patients were identified. The Chinese population-adjusted creatinine (Cr)-based European Kidney Function Consortium equation (EKFC-eGFRCr[CN]) had the smallest impact on dosing adjustments (3.4%), whereas the cystatin(Cys)-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (CKD-EPI-eGFRCys) had the largest impact (16.0%) and exhibited favorable performance in target vancomycin trough concentration (C Conclusion: Our study found that the CKD-EPI-eGFRCys equation required the most dosing adjustments, while the EKFC-eGFRCr(CN) equation required the fewest. Preferentially using the CKD-EPI-eGFRCys equation was optimal for target attainment of key clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.